Imexhs Limited
IME.ASXHealth Care
Providing leading medical imaging software to healthcare facilities.
Market Data
$0.350
-0.1%$18.9M
-100000.0x
$-0.060
0.00%
+0.0%
Latest Earnings
Appendix 4E & Annual Report 2025
27 February 2026
IMEXHS Limited (ASX: IME) delivered FY25 revenue of $29.0M, up 9.5% year-on-year, meeting the top end of its previously issued guidance range of $27.5–$28.2M. Underlying EBITDA more than tripled to $1.6M (vs $0.5M in FY24), driven by improved operating leverage and a significant turnaround in the RIMAB radiology services division. The company enters FY26 in a stronger financial position with net debt reduced to $0.5M, cash of $3.3M, and ARR of $34.8M (up 16% YoY), though it continues to report a net loss of $2.9M and carries a going concern emphasis of matter in the audit opinion. Key points: Revenue of $29.0M, up 9.5% YoY and at the top end of guidance ($27.5–$28.2M range), or +6% on a constant currency basis; Underlying EBITDA more than tripled to $1.6M vs $0.5M in pcp, with a strong H2 contribution of $1.3M demonstrating accelerating operating leverage; ARR of $34.8M, up 16% YoY (7% on constant currency basis), reinforcing recurring revenue quality across both Software ($11.8M) and Radiology Services ($23.0M)
Recent Announcements
Appendix 4E & Annual Report 2025
IMEXHS Limited (ASX: IME) delivered FY25 revenue of $29.0M, up 9.5% year-on-year, meeting the top end of its previously issued guidance range of $27.5–$28.2M. Underlying EBITDA more than tripled to $1.6M (vs $0.5M in FY24), driven by improved operating leverage and a significant turnaround in the RIMAB radiology services division. The company enters FY26 in a stronger financial position with net debt reduced to $0.5M, cash of $3.3M, and ARR of $34.8M (up 16% YoY), though it continues to report a net loss of $2.9M and carries a going concern emphasis of matter in the audit opinion. Key points: Revenue of $29.0M, up 9.5% YoY and at the top end of guidance ($27.5–$28.2M range), or +6% on a constant currency basis; Underlying EBITDA more than tripled to $1.6M vs $0.5M in pcp, with a strong H2 contribution of $1.3M demonstrating accelerating operating leverage; ARR of $34.8M, up 16% YoY (7% on constant currency basis), reinforcing recurring revenue quality across both Software ($11.8M) and Radiology Services ($23.0M)
Get real-time alerts for IME
Receive AI-powered earnings summaries and instant notifications when Imexhs Limited releases results.
Register Free